Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s175. https://doi.org/10.25251/skin.7.supp.175